<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323115</url>
  </required_header>
  <id_info>
    <org_study_id>D0536</org_study_id>
    <nct_id>NCT00323115</nct_id>
  </id_info>
  <brief_title>Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be
      treated with radiotherapy/chemotherapy followed by dendritic cell vaccine. Chemotherapy will
      be administered after three vaccinations for one year or until progression of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two to six weeks after surgery, patients with newly diagnosed glioblastoma multiforme (GBM)
      will undergo a six-week course of radiotherapy with concurrent chemotherapy (temozolomide).
      Between three and seven weeks after completing radiotherapy/chemotherapy, patients will
      undergo leukapheresis to collect white blood cells. These cells will be grown into dendritic
      cells, and cultured with tumor cells from the individual patient. Vaccinations will be given
      every two weeks for a total of three vaccinations. Four weeks after the third vaccination
      patients will resume chemotherapy for one year or until disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor-specific Cytotoxic T-cell Response</measure>
    <time_frame>Day 42</time_frame>
    <description>MRI &amp; pheresis post vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility and Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination</measure>
    <time_frame>Pheresis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)and Overall Survival (OS) Comparison to Prognostic Matched Historical Controls</measure>
    <time_frame>From Enrollment - March 2011</time_frame>
    <description>PFS will be assessed for each patient as the time from surgery until the patient reaches objective disease progression by MRI, defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of contrast enhancement of any lesion or any new enhancing tumor on MRI or CT scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Parameters With PFS vs Overall Survival</measure>
    <time_frame>Evaluable patients for immunologic parameters are those who have completed 3 vaccines</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Response When There is Residual Enhancing Tumor at Baseline MRI</measure>
    <time_frame>MRI post vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Dendritic Cell</intervention_name>
    <description>Vaccine given by cervical lymph node injection 3 times every other week</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>RT is standard of care (SOC) post surgery</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic Cell Vaccine</intervention_name>
    <description>Vaccine given cervical lymphnode injection 3 times every other week</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven GBM with central pathology review at Dartmouth-Hitchcock Medical
             Center (DHMC)

          -  Tumor specimen obtained at the time of surgery adequate for vaccination

          -  18 years of age or older

          -  Karnofsky Performance Status 60% or greater

          -  Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10 9th/L

          -  Platelets greater than or equal to 100 x 10 9th/L

          -  Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) less than or equal
             to 5 times the upper limits of normal (ULN)

          -  Total bilirubin less than or equal to 1.5 times ULN

          -  Serum creatinine less than or equal to 1.5 times ULN, OR estimated creatinine
             clearance greater than or equal to 60 mL/min

          -  No known immunosuppression other than chemo-related

          -  Negative HIV serologies

          -  No evidence of acute or chronic hepatitis on standard hepatitis C and B screening
             tests

          -  No chemotherapy within four weeks prior to leukapheresis

          -  Radiotherapy at outside institution is permitted if tissue was obtained at time of
             surgery at DHMC and patient is willing to follow-up per protocol

          -  Off steroids for at least two weeks before leukapheresis

          -  No second malignancies except non-melanoma skin cancer, and non-invasive cancer such
             at cervical CIS, superficial bladder cancer or breast CIS

          -  Negative serum or urine pregnancy test for women of childbearing potential

          -  No serious uncontrolled medical disorder or active infection

          -  All patients must give informed consent

          -  No history of clinical evidence of active autoimmune disease

        Exclusion Criteria:

          -  Invasive cancers in the past 5 years

          -  Rheumatologic/autoimmune disease

          -  Pregnancy or unwillingness to remain on acceptable form of birth control during study

          -  Major cardiac, pulmonary, or other systemic disease; viral hepatitis; HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilo E. Fadul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011 May;34(4):382-9. doi: 10.1097/CJI.0b013e318215e300.</citation>
    <PMID>21499132</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <results_first_submitted>August 24, 2012</results_first_submitted>
  <results_first_submitted_qc>August 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2012</results_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>cancer vaccine</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between May 2006 and February 2008, 60 patients were diagnosed with GBM at our institution. Of 11 patients who entered the study, 1 had a seizure with neurologic deterioration several weeks after leukapheresis and did not receive any DC vaccinations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme (GBM) will be treated with radiotherapy and concurrent chemotherapy followed by intranodal vaccine with autologous dendritic cells (DCs) primed with tumor lysate. Adjuvant chemotherapy will be administered after vaccination for 1 year or until tumor progression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccine Administration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Adjuvant Therapy &amp; Survival Follow-Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme (GBM) will be treated with radiotherapy and concurrent chemotherapy followed by intranodal vaccine with autologous dendritic cells (DCs) primed with tumor lysate. Adjuvant chemotherapy will be administered after vaccination for 1 year or until tumor progression</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.273" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor-specific Cytotoxic T-cell Response</title>
        <description>MRI &amp; pheresis post vaccine</description>
        <time_frame>Day 42</time_frame>
        <population>All participants who received all 3 vaccine administrations were used in this data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme (GBM) will be treated with radiotherapy and concurrent chemotherapy followed by intranodal vaccine with autologous dendritic cells (DCs) primed with tumor lysate. Adjuvant chemotherapy will be administered after vaccination for 1 year or until tumor progression</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor-specific Cytotoxic T-cell Response</title>
          <description>MRI &amp; pheresis post vaccine</description>
          <population>All participants who received all 3 vaccine administrations were used in this data analysis.</population>
          <units>10^9 cells/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. CD4+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" lower_limit="0.198" upper_limit="0.921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. CD8+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4836" lower_limit="0.135" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility and Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination</title>
        <time_frame>Pheresis</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)and Overall Survival (OS) Comparison to Prognostic Matched Historical Controls</title>
        <description>PFS will be assessed for each patient as the time from surgery until the patient reaches objective disease progression by MRI, defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of contrast enhancement of any lesion or any new enhancing tumor on MRI or CT scans.</description>
        <time_frame>From Enrollment - March 2011</time_frame>
        <population>Surviving patients with no disease progression as of 3/11 - the date used for data collection for publication.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme (GBM) will be treated with radiotherapy and concurrent chemotherapy followed by intranodal vaccine with autologous dendritic cells (DCs) primed with tumor lysate. Adjuvant chemotherapy will be administered after vaccination for 1 year or until tumor progression</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)and Overall Survival (OS) Comparison to Prognostic Matched Historical Controls</title>
          <description>PFS will be assessed for each patient as the time from surgery until the patient reaches objective disease progression by MRI, defined as greater than or equal to a 25% increase in the product of the largest perpendicular diameters of contrast enhancement of any lesion or any new enhancing tumor on MRI or CT scans.</description>
          <population>Surviving patients with no disease progression as of 3/11 - the date used for data collection for publication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunological Parameters With PFS vs Overall Survival</title>
        <time_frame>Evaluable patients for immunologic parameters are those who have completed 3 vaccines</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Response When There is Residual Enhancing Tumor at Baseline MRI</title>
        <time_frame>MRI post vaccine</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline through 30 days after last administration of vaccine.</time_frame>
      <desc>Participants who started in the &quot;Adjuvant Therapy&quot; Period were assessed for Other/Non-Serious Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme (GBM) will be treated with radiotherapy and concurrent chemotherapy followed by intranodal vaccine with autologous dendritic cells (DCs) primed with tumor lysate. Adjuvant chemotherapy will be administered after vaccination for 1 year or until tumor progression</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, neck, unilateral, Grade 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Camilo Fadul</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-653-6312</phone>
      <email>camilo.e.fadul@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

